Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Genetic Technologies Ltd is a diagnostics & research business based in the US. Genetic Technologies shares (GENE) are listed on the NASDAQ and all prices are listed in US Dollars. Genetic Technologies employs 52 staff and has a trailing 12-month revenue of around $9.2 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.24 |
|---|---|
| 52-week range | $0.95 - $3.27 |
| 50-day moving average | $1.50 |
| 200-day moving average | $1.66 |
| Wall St. target price | $12.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.60 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.24 from 2022-09-28
| 1 week (2022-09-23) | -4.62% |
|---|---|
| 1 month (2022-08-26) | N/A |
| 3 months (2022-06-28) | -3.88% |
| 6 months (2022-03-26) | N/A |
| 1 year (2021-09-30) | -59.87% |
|---|---|
| 2 years (2020-09-30) | -64.16% |
| 3 years (2019-09-30) | 1.9 |
| 5 years (2017-09-29) | 45.92% |
| Revenue TTM | $9.2 million |
|---|---|
| Gross profit TTM | $6.2 million |
| Return on assets TTM | -21.54% |
| Return on equity TTM | -37.57% |
| Profit margin | -77.36% |
| Book value | $1.20 |
| Market capitalisation | $21.5 million |
TTM: trailing 12 months
We're not expecting Genetic Technologies to pay a dividend over the next 12 months.
Genetic Technologies's shares were split on a 1:4 basis on 14 August 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genetic Technologies shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Genetic Technologies shares which in turn could have impacted Genetic Technologies's share price.
Over the last 12 months, Genetic Technologies's shares have ranged in value from as little as $0.95 up to $3.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genetic Technologies's is 1.282. This would suggest that Genetic Technologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.